Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals has said that its drug for hepatitis C was found to be safe in a phase I study.
Subscribe to our email newsletter
The primary goal of the phase I study was to evaluate safety and pharmacokinetic properties of XTL-6865 in patients with chronic hepatitis C. XTL-6865, which targets the E2 envelope protein of the hepatitis C virus, is comprised of two fully-human monoclonal antibodies and is administered intravenously.
In this study, XTL-6865 was shown to be safe at high doses, up to 1200mg for five consecutive daily doses and a single dose of 2400mg. The study also enabled the company to establish the pharmacokinetic properties of XTL-6865 in patients with chronic hepatitis C. The study provided evidence of binding of the antibody to circulating virus and the formation of immune complexes(antibody-virus), believed to be important for virus neutralization in the serum.
“We believe that XTL-6865 could potentially play a role in certain clinical settings, such as preventing re-infection of hepatitis C following liver transplantation or in chronic hepatitis C patients who have low viral loads following treatment with other anti-hepatitis C drugs. We believe this is now an appropriate time to seek to out-license the compound,” said Ron Bentsur, CEO of XTL Biopharmaceuticals.